Fast, long-term relief from opioid dependence?

This week, the FDA could approve Braeburn Pharmaceuticals' buprenorphine implant, which provides up to six months continuous treatment for the withdrawal symptoms and cravings of opioid dependence.
Up Next
This week, the FDA could approve Braeburn Pharmaceuticals' buprenorphine implant, which provides up to six months continuous treatment for the withdrawal symptoms and cravings of opioid dependence.